Faeth Therapeutics director Karen H. Vousden files initial beneficial ownership statement
FTH•Initial beneficial ownership filing
Faeth Therapeutics director Karen H. Vousden reported 42,631 shares of common stock held directly as of Sept. 11, 2026.
